Funded by the Foundation through a grant from Pfizer Ophthalmics, the 2005 meeting is the first in a series of annual conferences designed to improve research and clinical care in areas of ophthalmology related to preventable vision loss and blindness. The First Author of the presentation is Peter A. Campochiaro, M.D., of the Department of Ophthalmology at Johns Hopkins University School of Medicine, Baltimore, Md.
"We are delighted to partner with ARVO to facilitate the advancement of science that will help everybody gain a better understanding of specific diseases that lead to blindness," said Robert Besthof, world wide commercial leader, Pfizer Ophthalmology.
Topics and organizers of this meeting were selected by an independent selection committee which reviewed an open call for proposals related to angiogenesis, neovascularization, and vasoproliferation. An international, interdisciplinary panel of expert speakers was then solicited, forming the First ARVO/Pfizer Ophthalmics Research Institute Working Group .
The topic of the 2006 ARVO/Pfizer Ophthalmics Research Institute meeting will be "Aqueous Humor Outflow: What Do We Know, Where Will It Lead Us?" to be held April 28-29, 2006 in Fort Lauderdale, FL. The research presented at this meeting will be published in a future issue of IOVS.
Founded in 2002, the ARVO Foundation for Eye Research is a supporting organization of the Association for Research in Vision and Ophthalmology (ARVO). The Foundation provides continuing education and stable support for original and innovative vision research, particularly with translational impact fostering collaboration between clinicians and basic scientists. The Foundation also supports training for new vision research scientists, including those in developing countries. For more information about the ARVO Foundation for Eye Research, logon to www.arvofoundation.org.
Pfizer Ophthalmics, a division of Pfizer Inc., is committed to preserving sight and eliminating preventable blindness. Pfizer Ophthalmics discovers, develops and provides leading treatments in ophthalmology to support patients who are at risk of blindness or suffering from vision impairment, and to serve the health care professionals who treat them. Its current product line includes the most prescribed treatment to lower elevated eye pressure in patients with ocular hypertension (abnormally high eye pressure) or open-angle glaucoma. In collaboration with OSI Pharmaceuticals, Inc., the division also includes a treatment for neovascular age-related macular degeneration.
ARVO is a membership organization of more than 11,300 eye and vision researchers from over 70 countries. Established in 1928, the Association encourages and assists its members and others in research, training, publication, and dissemination of knowledge in vision and ophthalmology. ARVO's headquarters are located in Rockville, Md. For more information about ARVO, logon to www.arvo.org.
Investigative Ophthalmology & Visual Science (IOVS), published monthly in print and online, is an official journal of the Association for Research in Vision and Ophthalmology (ARVO). Included are original contributions that emphasize clinical and laboratory hypothesis-based research with statistically good results that clearly advance the fields of ophthalmic and vision research. For more information, logon to www.iovs.org.
Journal
Investigative Ophthalmology & Visual Science